Literature DB >> 27822096

The Danish Lung Cancer Registry.

Erik Jakobsen1, Torben Riis Rasmussen2.   

Abstract

AIM OF DATABASE: The Danish Lung Cancer Registry (DLCR) was established by the Danish Lung Cancer Group. The primary and first goal of the DLCR was to improve survival and the overall clinical management of Danish lung cancer patients. STUDY POPULATION: All Danish primary lung cancer patients since 2000 are included into the registry and the database today contains information on more than 50,000 cases of lung cancer. MAIN VARIABLES: The database contains information on patient characteristics such as age, sex, diagnostic procedures, histology, tumor stage, lung function, performance, comorbidities, type of surgery, and/or oncological treatment and complications. Since November 2013, DLCR data on Patient -Reported Outcome Measures is also included. DESCRIPTIVE DATA: Results are primarily reported as quality indicators, which are published online monthly, and in an annual report where the results are commented for local, regional, and national audits. Indicator results are supported by descriptive reports with details on diagnostics and treatment.
CONCLUSION: DLCR has since its creation been used to improve the quality of treatment of lung cancer in Denmark and it is increasingly used as a source for research regarding lung cancer in Denmark and in comparisons with other countries.

Entities:  

Keywords:  comorbidities; diagnostic procedures; histology; lung cancer; lung function; oncological treatment; performance; treatment complications; tumor stage; type of surgery

Year:  2016        PMID: 27822096      PMCID: PMC5094603          DOI: 10.2147/CLEP.S99458

Source DB:  PubMed          Journal:  Clin Epidemiol        ISSN: 1179-1349            Impact factor:   4.790


Aim of database

The Danish Lung Cancer Registry (DLCR) was established by the Danish Lung Cancer Group (DLCG). The primary goal of DLCG and later of the DLCR was to improve survival and the clinical management of Danish lung cancer patients. A secondary aim has been to produce a platform for lung cancer research. DLCG was established in 1991 and representatives from medical specialties working with lung cancer were invited to participate. Several published papers indicated that the survival of lung cancer patients in Denmark was inferior to international standards and that no improvement in the relative 5-year survival had been observed for several years.1–3 It was the general perception among experts that the only way to reduce the number of deaths from lung cancer was to intensify the public campaigns against smoking.4 In 1990, more than 90 departments took part in diagnostics and treatment of lung cancer in Denmark, and a survey performed by the DLCG demonstrated major variation in the clinical management. The DLCG therefore decided to create a set of national guidelines for the management of lung cancer in Denmark. The first edition was published in 1998 and the DLCG adopted a strategy to implement the guidelines and concurrently monitor the implementation by reporting to a new registry established by the DLCR. The first patient was included in DLCR on January 1, 2000.

Study population

All Danish lung cancer patients are included into the registry. With the currently used methods for retrieving information about Danish lung cancer cases, the inclusion of incident cases since 2003 is estimated to be above 95% and the database today contains data on more than 55,000 cases of lung cancer including cancer of the trachea. Between 2000 and 2002, clinicians identified and reported patients to DLCR, but since 2003, the lung cancer patients are identified in the Danish National Patient Registry (DNPR),5 where the first occurrence of the diagnostic codes DC34 and DC33 according to the International Classification of Diseases, 10th Revision (ICD-10) is identified. These patients and their activities (procedures and treatments) form a basic database with information derived from the DNPR and the Danish Pathology Register (DPR)6 data alone. Subsequently, the basic database is used as a source for building the final qualified database (DLCR), which is on variable level validated and supplemented online by clinicians. All departments involved in the diagnosis and treatment of lung cancer in Denmark participate in DLCR and are responsible for the validation and supplementation of data. Since the participation is mandatory by law, data completeness is very high (more than 90%). Data on comorbidity is obtained from the DNPR.

Main variables

The database today contains information on patient characteristics such as age, sex, diagnostic procedures, histology, tumor stage, lung function, performance, comorbidities, type of surgery, and/or oncological treatment and complications registered. Information on vital status for each patient is retrieved from the Danish Civil Registration System.7 Age at time of diagnosis and sex are inferred from the personal identification number (PIN), a unique system identifying age and sex of all Danish citizens. Since November 2013, DLCR also has Patient-Reported Outcome Measures (PROMs), the first year after treatment has finalized. PROMs are evidence of patient-experienced health status, and are be applied to evaluate the experiences and needs of the lung cancer patients. Monitoring symptoms, functional capacity, and quality of life have the potential to improve quality and the result of treatment effort. The European Organization for Research and Treatment of Cancer (EORTC) 30 and EORTC-LC13 are used as questionnaire.8,9 The recorded diagnostic procedures are the procedures performed in cases suspected of lung cancer to diagnose the disease and the type of lung cancer, and to conclude on treatment options based on these informations and the staging of the lung cancer, lung function, the performance of the patient, and relevant comorbidities. DLCR also provide data concerning delays in the diagnostic evaluation and treatment. For the classification of comorbidity, the Charlson’s comorbidity index10 is used. Details on surgical treatment are recorded including dates, type of surgery, and complications. Information on primary oncological treatment includes the amount and type of radiation therapy, and the type and duration of chemotherapy.

Follow-up

After the primary treatments are finalized, all patients are offered to enter a follow-up program consisting of clinical controls and computed tomography scans in fixed intervals. The contents of and time spacing between the follow-up visits are according to national guidelines on follow-up of lung cancer, and these procedures together with information on treatment of recurrence are registered in the DLCR. The patient’s vital status is updated in the database once a month.

Examples of research

The first peer-reviewed articles based on the data in DLCR were published in 2009 and since an increasing number of papers have been published yearly. Publications based on the DLCR are yearly listed in the annual report.11 A number of papers have focused on documenting the effects of a national clinical database such as the DLCR. Thus, Jakobsen et al12 in 2013 published a work entitled “Nationwide quality improvement in lung cancer care: the Danish Lung Cancer Registry,” in which they conclude “that a comprehensive national quality management system including national guidelines, a database with high data quality and completeness, frequent reports to the professionals and the public, audit and commitment from all stakeholders can contribute to improve practice and results and reduce regional differences.” Table 1 shows the quality indicators used in DLCR in 2013. These indicators are continuously being evaluated and revised. Figure 1 is an example on how the indicators are reported in the annual reports. This indicator shows the degree of accordance between the clinical stage of the lung cancer and postoperative stage and is one of the most important quality indicators of the diagnostic set up. The higher accordance, the better quality of the diagnostic set up and the higher the probability of the patient receiving the optimal treatment. The indicator shows the different result in the five Danish regions.
Table 1

The quality indicators used in DLCR in 2014

Indicator groupNumberIndicatorTypeThreshold (%)Time referencePrognostic factorsAdjustments
I. Survival, overallIaProportion of patients, surviving 1 year from date of diagnosisOutcome42Date of diagnosisClinical stageHistologyRegionYear of diagnosisOperation (yes/no)ComorbidityAgeSex
IbProportion of patients, surviving 2 years from date of diagnosisOutcome22
IcProportion of patients, surviving 5 years from date of diagnosisOutcome12
II. Survival, after surgeryIIaProportion of patients, surviving 30 days from date of operationOutcome97Date of operationClinical stageType of operationRegionYear of operationComorbidityAgeSex
IIbProportion of patients, surviving 1 year from date of operationOutcome75
IIcProportion of patients, surviving 2 years from date of operationOutcome65
IIdProportion of patients, surviving 5 years from date of operationOutcome40
III. Waiting timesIIIaProportion of patients operated within 42 days after referralStructural85Date of operationYear of treatmentDepartmentRegionAgeSex
IIIbProportion of patients starting oncologic treatment within 42 days after referralStructural85Date of first oncologic treatment
IIIcProportion of patients starting chemotherapy within 42 days after referralStructural85Date of first chemotherapy
IIIdProportion of patients starting radiotherapy within 42 days after referralStructural85Date of first radiotherapy
IIIeProportion of patients starting chemotherapy and radiotherapy within 42 days after referralStructural85Date of first chemotherapy and radiotherapy
IV. Stage classificationIVProportion of patients with accordance between cTNM and pTNMProcess85Date of operationDepartmentRegionYear of operationAgeSex
V. Resection rateVProportion of patients with NSCLC who had a resectionProcess20Date of operationRegionYear of diagnoseComorbidityAgeSex

Abbreviations: DLCR, Danish Lung Cancer Registry; cTNM, clinical stage of the lung cancer; NSCLC, non-small-cell lung cancer; TNM, tumor node metastasis; pTNM, postoperative stage.

Figure 1

Time trends in the accordance between cTNM and pTNM across health care region.

Abbreviations: cTNM, clinical stage of the lung cancer; TNM, tumor node metastasis; pTNM, postoperative stage.

The research based on the data in DLCR furthermore has focused on two main topics, comorbidity and inequality. In four consecutive articles, the importance of comorbidity in lung cancer treatment and survival has been evaluated.13–16 Socioeconomic position and different aspects of lung cancer have been explored in another series of papers with the overall conclusion that socioeconomic position is a major prognostic factor in lung cancer survival and treatment.17–19 These and other publications document the growing importance of national and international cooperation in lung cancer research.

Administrative issues and funding

DLCR is one of the national supported databases organized under the administration of the Joint Secretariat for the Danish Clinical Quality Improvement Program (Databasernes Fælles-sekretariat, Regionernes Kliniske Kvalitetsudviklings program, RKKP). Furthermore, the DLCG is a part of the Danish Multidisciplinary Cancer Groups (DMCG.dk), a national network of physicians and other health care professionals, scientists, and government officials committed to improving cancer care in Denmark. Funding is through the Danish Clinical Quality Improvement Program. Data in the clinical databases connected to RKKP including DLCR are on application to the organizations available for all Danish researchers.

Conclusion

DLCR contains information on every incident primary case of lung cancer in Denmark since 2003. The variables include patient age, sex, diagnostic procedures, histology, tumor stage, lung function, performance, comorbidities, type of surgery, and/or oncological treatment, complications registered, and the patient’s vital status. Since November 2013, DLCR also have included PROMs the first year after treatment has been finalized. DLCR has, since its creation, been used to improve the quality of treatment of lung cancer in Denmark and it is increasingly used as a source for research regarding lung cancer in Denmark and in comparisons with other countries.
  18 in total

1.  The Danish Pathology Register.

Authors:  Beth Bjerregaard; Ole B Larsen
Journal:  Scand J Public Health       Date:  2011-07       Impact factor: 3.021

2.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

3.  [Lung cancer--better prognosis?].

Authors:  K B Andersen
Journal:  Ugeskr Laeger       Date:  1994-08-15

4.  The Danish Civil Registration System.

Authors:  Carsten Bøcker Pedersen
Journal:  Scand J Public Health       Date:  2011-07       Impact factor: 3.021

5.  The effect of different comorbidities on survival of non-small cells lung cancer patients.

Authors:  Maria Iachina; Erik Jakobsen; Henrik Møller; Margreet Lüchtenborg; Anders Mellemgaard; Mark Krasnik; Anders Green
Journal:  Lung       Date:  2014-12-17       Impact factor: 2.584

6.  The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life.

Authors:  B Bergman; N K Aaronson; S Ahmedzai; S Kaasa; M Sullivan
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

7.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

8.  Cancer in the Nordic countries, 1981-86. A joint publication of the five Nordic Cancer Registries.

Authors:  H Tulinius; H H Storm; E Pukkala; A Andersen; J Ericsson
Journal:  APMIS Suppl       Date:  1992

9.  Survival of Danish cancer patients 1943-1987. Respiratory system.

Authors:  J Hansen; J H Olsen
Journal:  APMIS Suppl       Date:  1993

10.  Socioeconomic position, stage of lung cancer and time between referral and diagnosis in Denmark, 2001-2008.

Authors:  S O Dalton; B L Frederiksen; E Jacobsen; M Steding-Jessen; K Østerlind; J Schüz; M Osler; C Johansen
Journal:  Br J Cancer       Date:  2011-09-06       Impact factor: 7.640

View more
  11 in total

1.  VATS lobectomy: does surgical heterogeneity prevent evidence on pain control?

Authors:  Luigi Santambrogio; Valeria Musso
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

2.  VATS lobectomy vs. open lobectomy for early-stage lung cancer: an endless question-are we close to a definite answer?

Authors:  Francesco Guerrera; Anne Olland; Enrico Ruffini; Pierre-Emmanuel Falcoz
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

3.  Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study).

Authors:  Mariano Provencio; Enric Carcereny; Delvys Rodríguez-Abreu; Rafael López-Castro; María Guirado; Carlos Camps; Joaquim Bosch-Barrera; Rosario García-Campelo; Ana Laura Ortega-Granados; José Luis González-Larriba; Joaquín Casal-Rubio; Manuel Domine; Bartomeu Massutí; María Ángeles Sala; Reyes Bernabé; Juana Oramas; Elvira Del Barco
Journal:  Transl Lung Cancer Res       Date:  2019-08

4.  National quality registries: how to improve the quality of data?

Authors:  Fieke Hoeijmakers; Naomi Beck; Michel W J M Wouters; Hubert A Prins; Willem H Steup
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

Review 5.  Implementation of lung cancer multidisciplinary teams: a review of evidence-practice gaps.

Authors:  Nicole M Rankin; Elizabeth A Fradgley; David J Barnes
Journal:  Transl Lung Cancer Res       Date:  2020-08

6.  Comorbidity among Danish lung cancer patients before and after initial cancer diagnosis.

Authors:  Anja Gouliaev; Ole Hilberg; Niels Lyhne Christensen; Torben Rasmussen; Rikke Ibsen; Anders Løkke
Journal:  Eur Clin Respir J       Date:  2020-12-20

7.  Cancer Incidence and Risk of Multiple Cancers after Environmental Asbestos Exposure in Childhood-A Long-Term Register-Based Cohort Study.

Authors:  Sofie Bünemann Dalsgaard; Else Toft Würtz; Johnni Hansen; Oluf Dimitri Røe; Øyvind Omland
Journal:  Int J Environ Res Public Health       Date:  2021-12-27       Impact factor: 3.390

8.  Inflammation-scores as prognostic markers of overall survival in lung cancer: a register-based study of 6,210 Danish lung cancer patients.

Authors:  Anne Winther-Larsen; Ninna Aggerholm-Pedersen; Birgitte Sandfeld-Paulsen
Journal:  BMC Cancer       Date:  2022-01-14       Impact factor: 4.430

9.  Pretreatment Albumin-to-Alkaline Phosphatase Ratio Is a Prognostic Marker in Lung Cancer Patients: A Registry-Based Study of 7077 Lung Cancer Patients.

Authors:  Birgitte Sandfeld-Paulsen; Ninna Aggerholm-Pedersen; Anne Winther-Larsen
Journal:  Cancers (Basel)       Date:  2021-12-06       Impact factor: 6.639

10.  Increased use of diagnostic CT imaging increases the detection of stage IA lung cancer: pathways and patient characteristics.

Authors:  Charlotte Hyldgaard; Christian Trolle; Stefan Markus Walbom Harders; Henriette Engberg; Torben Riis Rasmussen; Henrik Møller
Journal:  BMC Cancer       Date:  2022-04-27       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.